WCN26-4433 SHORT-TERM CLINICAL OUTCOMES OF A NEW HOME HEMODIALYSIS PROGRAM USING NXSTAGE SYSTEM ONE IN A SINGLE CENTER

Introduction:The treatment method of osteoporosis in patients undergoing hemodialysis (HD) has not been established, as there is insufficient evidence regarding the treatment of osteoporosis.The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 guidelines suggest that determining the bone marrow density (BMD) of HD patients is useful.In 2018, we began treating HD patients' osteoporosis with denosumab.Herein, we describe the effects of the treatment.Methods: This was a single-center prospective observational study of 42 HD patients (age 71.29.7 yrs; 24 females, 18 males) treated for osteoporosis with denosumab in our hospital during 2018-2024.The average observational period was 3.82.2years.We introduced osteoporosis treatment with alendronate in 2011, ibandronate in 2016, and denosumab in 2018.The patients' BMD values including the lumbar spine, femoral neck, and total hip were determined by dual-energy Xray absorptiometry.We administered alendronate or ibandronate to patients whose first T-score was #-2.5.We checked the patients' BMD measured every year from 2011.Beginning in 2018, if a patient's Tscore did not improve after the second year, we changed the